We are live on
!
Find out more
FCMI
Foresite Capital Management III Portfolio holdings
AUM
$37.9M
1-Year Est. Return
6.87%
This Fund
S&P 500
This Quarter
Est. Return
-26.19%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$62.8M
AUM Growth
-$116M
(-65%)
Cap. Flow
-$80.7M
Cap. Flow
% of AUM
-128.53%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
13
New
3
Increased
2
Reduced
3
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BPMC
Blueprint Medicines
BPMC
|
+$10.9M |
| 2 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$3.78M |
| 3 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$2.85M |
| 4 |
KYNB
Kyntra Bio
KYNB
|
+$1.59M |
| 5 |
EPZM
Epizyme, Inc
EPZM
|
+$567K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AERI
Aerie Pharmaceuticals
AERI
|
+$37.8M |
| 2 |
IMMU
Immunomedics Inc
IMMU
|
+$22.7M |
| 3 |
XLRN
Acceleron Pharma
XLRN
|
+$16.5M |
| 4 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
+$13.9M |
| 5 |
Replimune Group
REPL
|
+$4.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MYOK
1
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $18.1M | 28.77% |
385,452
+58,970
| +18% | +$3.78M |
|
|
EPZM
2
DELISTED
Epizyme, Inc
EPZM
| $11.1M | 17.63% |
713,812
+26,385
| +4% | +$567K |
|
|
BPMC
3
DELISTED
Blueprint Medicines
BPMC
| $9.94M | 15.82% |
+169,900
| New | +$10.9M |
|
4
Natera
NTRA
$36.5B
| $6.23M | 9.93% |
208,768
| – | – |
|
|
IMMU
5
DELISTED
Immunomedics Inc
IMMU
| $5.39M | 8.59% |
400,000
-1,350,000
| -77% | -$22.7M |
|
|
AERI
6
DELISTED
Aerie Pharmaceuticals
AERI
| $4.81M | 7.66% |
356,492
-1,993,985
| -85% | -$37.8M |
|
|
XLRN
7
DELISTED
Acceleron Pharma
XLRN
| $3.78M | 6.01% |
42,030
-212,893
| -84% | -$16.5M |
|
|
BHVN
8
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $2.12M | 3.37% |
+62,245
| New | +$2.85M |
|
|
KYNB
9
Kyntra Bio
KYNB
$29M
| $1.39M | 2.21% |
+1,600
| New | +$1.59M |
|
10
Ascendis Pharma A/S
ASND
$16.3B
| – | – |
-13,922
| Closed | -$1.94M |
|
|
11
Replimune Group
REPL
$493M
| – | – |
-313,922
| Closed | -$4.5M |
|
|
CBAY
12
DELISTED
Cymabay Therapeutics
CBAY
| – | – |
-1,504,710
| Closed | -$2.95M |
|
|
BOLD
13
DELISTED
Audentes Therapeutics, Inc
BOLD
| – | – |
-233,067
| Closed | -$13.9M |
|
Similar funds
PIM
KCGDR
SEM
ALFIA
MCMI
LCM
HLC
KXA
Foresite Capital Management III's Q1 2020 Portfolio in Review
As of Q1 2020, Foresite Capital Management III held 13 positions worth $62.8M, down 65% from $178M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Foresite Capital Management III withdrew a net $80.7M in Q1 2020, closing 4 positions and reducing 3 holdings. Its most notable exit was Audentes Therapeutics, Inc, an estimated $13.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 47% a quarter earlier.
Against the trend, Foresite Capital Management III opened a new position in Blueprint Medicines worth $9.94M.
- Foresite Capital Management III's largest Q1 2020 buy was Blueprint Medicines: 169,900 shares worth $9.94M.
- Foresite Capital Management III added most to MyoKardia, Inc. Common Stock in Q1 2020, an estimated $3.78M increase.
- Foresite Capital Management III's biggest Q1 2020 reduction was Aerie Pharmaceuticals, cutting an estimated $37.8M.
- Foresite Capital Management III fully exited Audentes Therapeutics, Inc in Q1 2020, selling an estimated $13.9M.
- Foresite Capital Management III's ten largest holdings make up 100% of its $62.8M portfolio in Q1 2020.
- Foresite Capital Management III opened 3 new positions and closed 4 in Q1 2020.
- Foresite Capital Management III's portfolio value fell 65% quarter-over-quarter to $62.8M.
Based on Foresite Capital Management III's 13F filing for Q1 2020, filed 14 May 2020.